HootDex Logo

Serina Therapeutics shares jumped nearly 35% after the FDA cleared its IND application for SER-252, advancing plans for a Phase 1b trial in advanced Parkinson’s disease.

Importance Rank: 
1

read more

error: Content is protected !!